Application No. 08/819,669 Reply to Final Office Action of July 7, 2009 Docket No.: NY-LUD 5253-US5-DIV

## AMENDMENTS TO THE CLIAMS

Fax: 2123183400

Claims 1-182. (Canceled)

- An isolated, MAGE tumor rejection antigen precursor 183. (Previously presented) protein, wherein said protein is encoded by a nucleic acid molecule, the complementary sequence of which hybridizes to SEQ ID NO: 8 at 0.1xSSC, 0.1% SDS, wherein said tumor rejection antigen precursor is obtainable from melanoma cells.
- 184. (Previously presented) The isolated tumor rejection antigen precursor protein of claim 183, the amino acid sequence of which comprises the amino acid sequence set forth in SEQ ID NO: 26.
- The isolated tumor rejection antigen precursor protein 185. (Previously presented) of claim 183, wherein said protein is a human protein.
- Composition comprising the isolated tumor rejection 186. (Previously presented) antigen precursor protein of claim 183, and a pharmaceutically appropriate ingredient.
- Composition comprising the isolated tumor rejection 187. (Previously presented) antigen precursor protein of claim 184, and a pharmaceutically appropriate ingredient.
- (Previously presented) Composition comprising the isolated tumor rejection 188. antigen precursor protein of claim 185, and a pharmaceutically appropriate ingredient.

50225473.144

Fax: 2123183400

Application No. 08/819,669
Reply to Final Office Action of July 7, 2009

Docket No.: NY-LUD 5253-US5-DIV

- 189. (Previously presented) The composition of claim 186, in the form of a vaccine.
- 190. (Previously presented) The composition of claim 187, in the form of a vaccine.
- 191. (Previously presented) The composition of claim 188, in the form of a vaccine.
- 192. (Currently amended) The isolated MAGE tumor rejection antigen precursor protein of claim 183, wherein said protein is encoded by a nucleic acid molecule, the complementary sequence of which hybridizes to SEQ ID NO: 8 at 0.1xSSC, 0.1% SDS, wherein said tumor rejection antigen precursor is obtainable from melanoma cells and has an amino acid sequence encoded by a nucleotide sequence set forth in SEQ ID NO: 9, 11, or 13.
- 193. (Previously presented) The isolated tumor rejection antigen precursor of claim 192, wherein said nucleotide sequence is set forth in SEQ ID NO: 9.
- 194. (Previously presented) The isolated tumor rejection antigen precursor of claim 192, wherein said nucleotide sequence is set forth in SEQ ID NO: 11.
- 195. (Previously presented) The isolated tumor rejection antigen precursor of claim 192, wherein said nucleotide sequence is set forth in SEQ ID NO: 13.